Currently recruiting

Financial support available for mass switching of patients on BSRBR-RA


BSR are offering financial support to assist with the administration of registering groups of patients who are switching from a biologics to a biosimilars drug with the BSRBR-RA in 2017. This support can be for any requirement which will directly assist in the registering and re-registering of patients in a mass switching exercise. This could range from temporary additional staff to undertake the work or mail out costs for re-consenting patients by post. To apply please email bsrbr@rheumatology.org.uk outlining your requirements and estimate of number of patients to be switched. We will then work with you and your trust and aim to provide this assistance as seamlessly as possible.


RA Recruitment Pathway





Recruiting patients to the Rheumatoid Arthritis (RA) Register
To recruit patients or for more information on the RA Register, please email biologics.register@manchester.ac.uk.



AS Recruitment Pathway



Currently recruiting:

  • Enbrel (Etanercept)
  • Humira (Adalimumab)
  • Cimzia (Certolizumab Pegol)
  • Non-biologic drug control cohort
Register your unit to be able to recruit to the BSRBR-AS.
If you would like to recruit patients to the BSRBR-AS but are not currently registered please complete an expression of interest form and email to bsrbr-as@abdn.ac.uk.



Further information

CLRN support is available in England. Please contact your local CLRN representative, our UK CRN ID is 7302. Other research support funding is available in Scotland, Northern Ireland and Wales. Please note that the follow up of all participants in both registers continues even if biologic therapy is switched or discontinued.

BSR would like to thank you for your assistance with these studies.